Plain-English translation of NCT05939167 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing mesenchymal stem cells—special cells that can reduce inflammation and help restore immune function—in people with advanced HIV disease whose CD4 count (a key immune measure) has dropped below 500. Researchers want to see if this treatment is safe and whether it can help the immune system recover without causing serious side effects.
Standard HIV medications work well for many people, but some patients with advanced disease don't respond well enough to restore their immune system. This medication has shown promise in early research for boosting immune recovery, but doctors need to confirm it actually works and is safe specifically for people at this late stage of HIV disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of three groups: a placebo (saline injection) group, a standard stem cell treatment group (3 transplants), or an enhanced treatment group (6 transplants). Over the course of the study, you would receive your assigned injections and attend regular clinic visits for blood tests and health monitoring to track your CD4 count, viral load, and any side effects. The study will carefully watch for safety and measure whether the treatment helps restore your immune system.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
China